Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy

FCC. Klouwer, BGP. Koot, K. Berendse, EM. Kemper, S. Ferdinandusse, KVK. Koelfat, M. Lenicek, FM. Vaz, M. Engelen, PLM. Jansen, RJA. Wanders, HR. Waterham, FG. Schaap, BT. Poll-The,

. 2019 ; 42 (2) : 303-312. [pub] 20190221

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20022863

INTRODUCTION: Currently, no therapies are available for Zellweger spectrum disorders (ZSDs), a group of genetic metabolic disorders characterised by a deficiency of functional peroxisomes. In a previous study, we showed that oral cholic acid (CA) treatment can suppress bile acid synthesis in ZSD patients and, thereby, decrease plasma levels of toxic C27 -bile acid intermediates, one of the biochemical abnormalities in these patients. However, no effect on clinically relevant outcome measures could be observed after 9 months of CA treatment. It was noted that, in patients with advanced liver disease, caution is needed because of possible hepatotoxicity. METHODS: An extension study of the previously conducted pretest-posttest design study was conducted including 17 patients with a ZSD. All patients received oral CA for an additional period of 12 months, encompassing a total of 21 months of treatment. Multiple clinically relevant parameters and markers for bile acid synthesis were assessed after 15 and 21 months of treatment. RESULTS: Bile acid synthesis was still suppressed after 21 months of CA treatment, accompanied with reduced levels of C27 -bile acid intermediates in plasma. These levels significantly increased again after discontinuation of CA. No significant changes were found in liver tests, liver elasticity, coagulation parameters, fat-soluble vitamin levels or body weight. CONCLUSIONS: Although CA treatment did lead to reduced levels of toxic C27 -bile acid intermediates in ZSD patients without severe liver fibrosis or cirrhosis, no improvement of clinically relevant parameters was observed after 21 months of treatment. We discuss the implications for CA therapy in ZSD based on these results.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20022863
003      
CZ-PrNML
005      
20201214124908.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jimd.12042 $2 doi
035    __
$a (PubMed)30793331
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Klouwer, Femke C C $u Department of Pediatric Neurology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
245    14
$a The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy / $c FCC. Klouwer, BGP. Koot, K. Berendse, EM. Kemper, S. Ferdinandusse, KVK. Koelfat, M. Lenicek, FM. Vaz, M. Engelen, PLM. Jansen, RJA. Wanders, HR. Waterham, FG. Schaap, BT. Poll-The,
520    9_
$a INTRODUCTION: Currently, no therapies are available for Zellweger spectrum disorders (ZSDs), a group of genetic metabolic disorders characterised by a deficiency of functional peroxisomes. In a previous study, we showed that oral cholic acid (CA) treatment can suppress bile acid synthesis in ZSD patients and, thereby, decrease plasma levels of toxic C27 -bile acid intermediates, one of the biochemical abnormalities in these patients. However, no effect on clinically relevant outcome measures could be observed after 9 months of CA treatment. It was noted that, in patients with advanced liver disease, caution is needed because of possible hepatotoxicity. METHODS: An extension study of the previously conducted pretest-posttest design study was conducted including 17 patients with a ZSD. All patients received oral CA for an additional period of 12 months, encompassing a total of 21 months of treatment. Multiple clinically relevant parameters and markers for bile acid synthesis were assessed after 15 and 21 months of treatment. RESULTS: Bile acid synthesis was still suppressed after 21 months of CA treatment, accompanied with reduced levels of C27 -bile acid intermediates in plasma. These levels significantly increased again after discontinuation of CA. No significant changes were found in liver tests, liver elasticity, coagulation parameters, fat-soluble vitamin levels or body weight. CONCLUSIONS: Although CA treatment did lead to reduced levels of toxic C27 -bile acid intermediates in ZSD patients without severe liver fibrosis or cirrhosis, no improvement of clinically relevant parameters was observed after 21 months of treatment. We discuss the implications for CA therapy in ZSD based on these results.
650    _2
$a aplikace orální $7 D000284
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a žlučové kyseliny a soli $x metabolismus $7 D001647
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kyselina cholová $x krev $x terapeutické užití $7 D019826
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a nemoci jater $x farmakoterapie $x metabolismus $7 D008107
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a peroxizomy $x metabolismus $7 D020675
650    _2
$a mladý dospělý $7 D055815
650    _2
$a Zellwegerův syndrom $x krev $x farmakoterapie $x metabolismus $7 D015211
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Koot, Bart G P $u Department of Pediatric Gastroenterology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Berendse, Kevin $u Department of Pediatric Neurology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Kemper, Elles M $u Department of Pharmacy, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Ferdinandusse, Sacha $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Koelfat, Kiran V K $u Department of Surgery, Maastricht University, Maastricht, The Netherlands.
700    1_
$a Lenicek, Martin $u Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Vaz, Frédéric M $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Engelen, Marc $u Department of Pediatric Neurology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
700    1_
$a Jansen, Peter L M $u Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Wanders, Ronald J A $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Waterham, Hans R $u Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
700    1_
$a Schaap, Frank G $u Department of Surgery, Maastricht University, Maastricht, The Netherlands. Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Aachen, Germany.
700    1_
$a Poll-The, Bwee Tien $u Department of Pediatric Neurology, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
773    0_
$w MED00002747 $t Journal of inherited metabolic disease $x 1573-2665 $g Roč. 42, č. 2 (2019), s. 303-312
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30793331 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214124908 $b ABA008
999    __
$a ok $b bmc $g 1595182 $s 1113539
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 42 $c 2 $d 303-312 $e 20190221 $i 1573-2665 $m Journal of inherited metabolic disease $n J Inherit Metab Dis $x MED00002747
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace